跳至主要内容
临床试验/JPRN-UMIN000011934
JPRN-UMIN000011934已完成未知

The impact of additive EPA or ezetimibe to statin therapy on the stabilization of vulnerable plaque; Assessment by OCT - The impact of additive EPA or ezetimibe to statin therapy on the stabilization of vulnerable plaque; Assessment by OCT

Kobe University Graduate School of Medicine0 个研究点目标入组 80 人开始时间: 2013年10月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients were excluded from the study if they (1) were already using statins or other lipid-lowering therapies, (2) had known hypersensitivity to statins or contrast, (3) had end-stage renal failure (serum creatinine [Cre] ≥ 2.0 mg/dL), (4) demonstrated hemodynamic and respiratory instability (e.g., cardiogenic shock, severe congestive heart failure), or (5) had no consent to participate.

研究者

发起方
Kobe University Graduate School of Medicine

相似试验